Please assess the completion status of the following clinical trial:

Trial Title: Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic stem cell transplantation with myeloablative or non-myeloablative conditioning regimens~* Patients must be at least 180 days from the allogeneic stem cell transplantation procedure~* Steroid refractory cGVHD, defined as having persistent symptoms and signs of GVHD despite the use of prednisone for at least 4 weeks in the preceding 12 months without complete resolution of signs and symptoms.~* Stable dose of corticosteroids for 4 weeks prior to enrollment~* No addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment.~* Adequate bone marrow, renal and hepatic function as outlined in the protocol~* 18 years of age or older~* ECOG Performance Status of 0-2~Exclusion Criteria:~* Ongoing prednisone requirement \> 1mg/kg/day (or equivalent)~* Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment~* Concurrent ECP therapy within 4 weeks prior to enrollment~* Post-transplant exposure to any novel immunosuppressive medication within 100 days prior to enrollment~* Donor lymphocyte infusion within 100 days prior to IL-2 therapy~* Active malignant disease relapse~* Active, uncontrolled infection~* Positive serologic test for Hepatitis B or a positive serologic or nucleic acid test for Hepatitis C~* HIV seropositivity~* Life expectancy \< 3 months~* Pregnancy or lactation~* Inability to comply with IL-2 treatment regimen~* Uncontrolled cardiac angina or symptomatic congestive heart failure~* Organ transplant (allograft) recipient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)

Based on this trial design, predict the completion outcome and termination type (if applicable).